C7869
CEP-701 hydrate
≥98% (HPLC), Flt-3 receptor tyrosine kinase inhibitor, powder
别名:
KT-5555 hydrate, Lestaurtinib hydrate
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C26H21N3O4 · xH2O
化学文摘社编号:
分子量:
439.46 (anhydrous basis)
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
产品名称
CEP-701 hydrate, ≥98% (HPLC)
SMILES string
O.C[C@]12O[C@H](C[C@]1(O)CO)n3c4ccccc4c5c6C(=O)NCc6c7c8ccccc8n2c7c35
InChI key
LPOQWFBZBJTLEO-GMEYHWBASA-N
InChI
1S/C26H21N3O4.H2O/c1-25-26(32,12-30)10-18(33-25)28-16-8-4-2-6-13(16)20-21-15(11-27-24(21)31)19-14-7-3-5-9-17(14)29(25)23(19)22(20)28;/h2-9,18,30,32H,10-12H2,1H3,(H,27,31);1H2/t18-,25+,26+;/m1./s1
assay
≥98% (HPLC)
form
powder
color
white
solubility
DMSO: >10 mg/mL
storage temp.
−20°C
Quality Level
Application
CEP-701 hydrate has been used as a tyrosine kinase inhibitor:
- to study its effects on early growth response protein (EGR) genes and nerve growth factor (NGF) stimulation in human epithelial cells
- as a supplement in reservoir solution for co-crystallization studies with human receptor-interacting protein kinase 4 (RIPK4)
- as an FMS-like tyrosine kinase 3 (FLT3) inhibitor-gold nanoparticle conjugate to study its effects on acute myeloid leukemia
Biochem/physiol Actions
CEP-701 hydrate, also known as Lestaurtinib, can repress Janus kinase 2/signal transducer and activator of transcription 5 (JAK2/STAT5) signaling by the specific inhibition of JAK2.
CEP-701 is a Flt-3 receptor tyrosine kinase inhibitor.
Features and Benefits
This compound is a featured product for Kinase Phosphatase Biology research. Click here to discover more featured Kinase Phosphatase Biology products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Tania Diaz et al.
PloS one, 6(4), e18856-e18856 (2011-05-03)
Standard cytotoxic chemotherapy for Hodgkin Lymphoma (HL) has changed little in 30 years; the treatment for patients with relapsed or refractory disease remains challenging and novel agents are under development. JAK/STAT constitutive activation plays an important role in the pathogenesis
Bobe Petrushev et al.
International journal of nanomedicine, 11, 641-660 (2016-03-02)
Every year, in Europe, acute myeloid leukemia (AML) is diagnosed in thousands of adults. For most subtypes of AML, the backbone of treatment was introduced nearly 40 years ago as a combination of cytosine arabinoside with an anthracycline. This therapy
Christine S Huang et al.
Structure (London, England : 1993), 26(5), 767-777 (2018-05-01)
Receptor-interacting protein kinase 4 (RIPK4) is a highly conserved regulator of epidermal differentiation. Members of the RIPK family possess a common kinase domain as well as unique accessory domains that likely dictate subcellular localization and substrate preferences. Mutations in human
Timea Simon et al.
Nanoscale research letters, 10(1), 466-466 (2015-12-03)
Releasing drug molecules at the targeted location could increase the clinical outcome of a large number of anti-tumor treatments which require low systemic damage and low side effects. Nano-carriers of drugs show great potential for such task due to their
M Rochman et al.
Mucosal immunology, 8(4), 785-798 (2014-11-13)
Although interleukin (IL)-13 and neurotrophins are functionally important for the pathogenesis of immune responses, the interaction of these pathways has not been explored. Herein, by interrogating IL-13-induced responses in human epithelial cells we show that neurotrophic tyrosine kinase receptor, type
商品
Discover Bioactive Small Molecules for Kinase Phosphatase Biology
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持